Stock TRX TISSUE REGENIX GROUP PLC
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Tissue Regenix Group plc

Equities

TRX

GB00BNTXR104

Market Closed - London S.E.
Other stock markets
 11:35:27 2024-04-26 am EDT 		5-day change 1st Jan Change
61.5 GBX 0.00% Intraday chart for Tissue Regenix Group plc 0.00% +18.27%
Mar. 19 Tissue Regenix annual loss narrows sharply as revenue jumps AN
Mar. 19 Earnings Flash (TRX.L) TISSUE REGENIX GROUP Reports FY23 Revenue $29.5M MT

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

1st Jan change Capi. Investor Rating ESG Refinitiv
TISSUE REGENIX GROUP PLC Stock Tissue Regenix Group plc
+18.27% 53.94M -
VEEVA SYSTEMS INC. Stock Veeva Systems Inc.
+4.36% 32.47B
C
PRO MEDICUS LIMITED Stock Pro Medicus Limited
+14.14% 7.45B
C-
SECTRA AB Stock Sectra AB
+22.93% 3.89B
B-
EVOLENT HEALTH, INC. Stock Evolent Health, Inc.
-16.29% 3.15B
C-
OMNICELL, INC. Stock Omnicell, Inc.
-25.96% 1.28B
B
LUNIT INC. Stock Lunit Inc.
-36.14% 1.09B -
B-SOFT CO.,LTD. Stock B-SOFT Co.,Ltd.
-35.42% 902M -
SIMULATIONS PLUS, INC. Stock Simulations Plus, Inc.
-0.13% 893M
C
VERADIGM INC. Stock Veradigm Inc.
-24.12% 857M -
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. TRX Stock
  4. Ratings Tissue Regenix Group plc